...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome
【24h】

Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome

机译:通过靶向溶酶体的含氮致氮的含氮致丙酰基苄基衍生物的设计,合成和生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

A series of novel nitrogen-containing macrocyclic bisbibenzyl derivatives was designed, synthesized, and evaluated for antiproliferative activity against three anthropic cancer cell lines. Among these novel molecules, the tri-O-alkylated compound 18a displayed the most potent anticancer activity against the A549, MCF-7, and k562 cancer cell lines, with IC50 values of 0.51, 0.23, and 0.19 mu M, respectively, which were obviously superior to those of the parent compound riccardin D, and were 3-10-fold better than those of the clinical used drug ADR. The bis-Mannich derivative lib also exhibited significantly enhanced antiproliferative potency, with submicromolar IC50 values. Structure-activity relationship analyses of these newly synthesized compounds were also performed. Mechanistic studies indicated that these compounds could target the lysosome to induce lysosomal membrane permeabilization, and could also induce cell death that displayed features characteristic of both apoptosis and necrosis. (C) 2017 Elsevier Masson SAS. All rights reserved.
机译:设计了一系列新的含氮的含氮大环苄基衍生物,合成,并评估了针对三个人类癌细胞系的抗增殖活性。在这些新的分子中,三-O-烷基化化合物18A呈现出对A549,MCF-7和K562癌细胞系的最有效的抗癌活性,分别为0.51,0.23和0.19μm的IC 50值显然优于母体复合Riccardin D的那些,并且比临床使用的药物ADR更好3-10倍。 BIS-MANNICH衍生物LIB还表现出显着增强的抗增殖效力,亚微粒溶胶IC50值。还进行了这些新合成化合物的结构活性关系分析。机械研究表明,这些化合物可以靶向溶酶体以诱导溶酶体膜透露性,并且还可以诱导细胞死亡,显示细胞凋亡和坏死的特征。 (c)2017年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号